An MRI-based Radiomics Nomogram in Predicting Histologic Grade of Non-muscle-invasive Bladder Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Apr 3

PMID 37007156

Authors

Longchao Li

Jing Zhang

Xia Zhe

Hongzhi Chang

Min Tang

Xiaoyan Lei

Li Zhang

Xiaoling Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Non-muscle-invasive bladder cancer (NMIBC) is categorized into high and low grades with different clinical treatments and prognoses. Thus, accurate preoperative evaluation of the histologic NMIBC grade through imaging techniques is essential.

Objectives: To develop and validate an MRI-based radiomics nomogram for individualized prediction of NMIBC grading.

Methods: The study included 169 consecutive patients with NMIBC (training cohort: n = 118, validation cohort: n = 51). A total of 3148 radiomic features were extracted, and one-way analysis of variance and least absolute shrinkage and selection operator were used to select features for building the radiomics score(Rad-score). Three models to predict NMIBC grading were developed using logistic regression analysis: a clinical model, a radiomics model and a radiomics-clinical combined nomogram model. The discrimination and calibration power and clinical applicability of the models were evaluated. The diagnostic performance of each model was compared by determining the area under the curve (AUC) in receiver operating characteristic (ROC) curve analysis.

Results: A total of 24 features were used to build the Rad-score. A clinical model, a radiomics model, and a radiomics-clinical nomogram model that incorporated the Rad-score, age, and number of tumors were constructed. The radiomics model and nomogram showed AUCs of 0.910 and 0.931 in the validation set, which outperformed the clinical model (0.745). The decision curve analysis also showed that the radiomics model and combined nomogram model yielded higher net benefits than the clinical model.

Conclusion: A radiomics-clinical combined nomogram model has the potential to be used as a non-invasive tool for the differentiating low-from high-grade NMIBCs.

Citing Articles

Using apparent diffusion coefficient maps and radiomics to predict pathological grade in upper urinary tract urothelial carcinoma.

Nai R, Wang K, Ma S, Xi Z, Zhang Y, Zhang X BMC Med Imaging. 2024; 24(1):355.

PMID: 39736546 PMC: 11686858. DOI: 10.1186/s12880-024-01540-w.

Precise vesical wall staging of bladder cancer in the era of precision medicine: has it been fulfilled?.

Nouh M, Ezz Eldin O Abdom Radiol (NY). 2024; .

PMID: 39725735 DOI: 10.1007/s00261-024-04786-8.

Contrast-enhanced computed tomography-based radiomics nomogram for predicting HER2 status in urothelial bladder carcinoma.

Peng J, Tang Z, Li T, Pan X, Feng L, Long L Front Oncol. 2024; 14:1427122.

PMID: 39206159 PMC: 11349509. DOI: 10.3389/fonc.2024.1427122.

Predicting preoperative muscle invasion status for bladder cancer using computed tomography-based radiomics nomogram.

Zhang R, Jia S, Zhai L, Wu F, Zhang S, Li F BMC Med Imaging. 2024; 24(1):98.

PMID: 38678222 PMC: 11055285. DOI: 10.1186/s12880-024-01276-7.

Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer Therapies.

Akin O, Lema-Dopico A, Paudyal R, Konar A, Chenevert T, Malyarenko D Cancers (Basel). 2023; 15(22).

PMID: 38001728 PMC: 10670574. DOI: 10.3390/cancers15225468.

References

Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

Mannelli L, Nougaret S, Vargas H, Do R . Advances in diffusion-weighted imaging. Radiol Clin North Am. 2015; 53(3):569-81. PMC: 4979318. DOI: 10.1016/j.rcl.2015.01.002. View

Li H, Liu L, Ding L, Zhang Z, Zhang M . Quantitative Assessment of Bladder Cancer Reflects Grade and Recurrence: Comparing of Three Methods of Positioning Region of Interest for ADC Measurements at Diffusion-weighted MR Imaging. Acad Radiol. 2018; 26(9):1148-1153. DOI: 10.1016/j.acra.2018.10.016. View

El-Assmy A, Abou-El-Ghar M, Mosbah A, El-Nahas A, Refaie H, Hekal I . Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol. 2009; 19(7):1575-81. DOI: 10.1007/s00330-009-1340-7. View

Wang H, Hu D, Yao H, Chen M, Li S, Chen H . Radiomics analysis of multiparametric MRI for the preoperative evaluation of pathological grade in bladder cancer tumors. Eur Radiol. 2019; 29(11):6182-6190. DOI: 10.1007/s00330-019-06222-8. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Zhang X, Xu X, Tian Q, Li B, Wu Y, Yang Z . Radiomics assessment of bladder cancer grade using texture features from diffusion-weighted imaging. J Magn Reson Imaging. 2017; 46(5):1281-1288. PMC: 5557707. DOI: 10.1002/jmri.25669. View

Sadow C, Silverman S, OLeary M, Signorovitch J . Bladder cancer detection with CT urography in an Academic Medical Center. Radiology. 2008; 249(1):195-202. DOI: 10.1148/radiol.2491071860. View

Mastroianni R, Brassetti A, Krajewski W, Zdrojowy R, Al Salhi Y, Anceschi U . Assessing the Impact of the Absence of Detrusor Muscle in Ta Low-grade Urothelial Carcinoma of the Bladder on Recurrence-free Survival. Eur Urol Focus. 2020; 7(6):1324-1331. DOI: 10.1016/j.euf.2020.08.007. View

10.

Zhou G, Chen X, Zhang J, Zhu J, Zong G, Wang Z . Contrast-enhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer. Eur J Radiol. 2014; 83(11):2013-8. DOI: 10.1016/j.ejrad.2014.08.012. View

11.

Gmeiner J, Garstka N, Helbich T, Shariat S, Baltzer P . Vesical Imaging Reporting and Data System (VI-RADS): Are the individual MRI sequences equivalent in diagnostic performance of high grade NMIBC and MIBC?. Eur J Radiol. 2021; 142:109829. DOI: 10.1016/j.ejrad.2021.109829. View

12.

Panebianco V, Narumi Y, Altun E, Bochner B, Efstathiou J, Hafeez S . Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018; 74(3):294-306. PMC: 6690492. DOI: 10.1016/j.eururo.2018.04.029. View

13.

Rosenkrantz A, Mussi T, Spieler B, Melamed J, Taneja S, Huang W . High-grade bladder cancer: association of the apparent diffusion coefficient with metastatic disease: preliminary results. J Magn Reson Imaging. 2012; 35(6):1478-83. DOI: 10.1002/jmri.23590. View

14.

Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Kawai T . Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology. 2009; 251(1):112-21. DOI: 10.1148/radiol.2511080873. View

15.

Leo M, McMullen C, OKeeffe-Rosetti M, Weinmann S, Garg T, Nielsen M . External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system. Urol Oncol. 2019; 38(2):39.e21-39.e27. DOI: 10.1016/j.urolonc.2019.10.003. View

16.

Panebianco V, De Berardinis E, Barchetti G, Simone G, Leonardo C, Grompone M . An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol. 2017; 27(9):3759-3766. DOI: 10.1007/s00330-017-4758-3. View

17.

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat E . EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016; 71(3):447-461. DOI: 10.1016/j.eururo.2016.05.041. View

18.

Turker P, Bostrom P, Wroclawski M, Van Rhijn B, Kortekangas H, Kuk C . Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int. 2012; 110(6):804-11. DOI: 10.1111/j.1464-410X.2012.10939.x. View

19.

Sevcenco S, Ponhold L, Heinz-Peer G, Fajkovic H, Haitel A, Susani M . Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. Urol Oncol. 2014; 32(8):1166-71. DOI: 10.1016/j.urolonc.2014.04.019. View

20.

van Rhijn B, Burger M, Lotan Y, Solsona E, Stief C, Sylvester R . Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009; 56(3):430-42. DOI: 10.1016/j.eururo.2009.06.028. View